全文获取类型
收费全文 | 1390494篇 |
免费 | 103119篇 |
国内免费 | 4402篇 |
专业分类
耳鼻咽喉 | 17514篇 |
儿科学 | 44788篇 |
妇产科学 | 37514篇 |
基础医学 | 205093篇 |
口腔科学 | 38188篇 |
临床医学 | 133885篇 |
内科学 | 271567篇 |
皮肤病学 | 27743篇 |
神经病学 | 116802篇 |
特种医学 | 49462篇 |
外国民族医学 | 366篇 |
外科学 | 191584篇 |
综合类 | 29020篇 |
现状与发展 | 1篇 |
一般理论 | 479篇 |
预防医学 | 119138篇 |
眼科学 | 29977篇 |
药学 | 102444篇 |
6篇 | |
中国医学 | 3375篇 |
肿瘤学 | 79069篇 |
出版年
2021年 | 11828篇 |
2019年 | 12605篇 |
2018年 | 18054篇 |
2017年 | 13302篇 |
2016年 | 14347篇 |
2015年 | 16879篇 |
2014年 | 22553篇 |
2013年 | 34571篇 |
2012年 | 49091篇 |
2011年 | 51654篇 |
2010年 | 29286篇 |
2009年 | 26529篇 |
2008年 | 46727篇 |
2007年 | 49221篇 |
2006年 | 49516篇 |
2005年 | 47674篇 |
2004年 | 45182篇 |
2003年 | 42790篇 |
2002年 | 41468篇 |
2001年 | 61966篇 |
2000年 | 63972篇 |
1999年 | 52984篇 |
1998年 | 14754篇 |
1997年 | 13392篇 |
1996年 | 13241篇 |
1995年 | 12579篇 |
1994年 | 11721篇 |
1993年 | 11015篇 |
1992年 | 41663篇 |
1991年 | 40851篇 |
1990年 | 39507篇 |
1989年 | 37409篇 |
1988年 | 34626篇 |
1987年 | 33735篇 |
1986年 | 32207篇 |
1985年 | 30700篇 |
1984年 | 23115篇 |
1983年 | 19645篇 |
1982年 | 11824篇 |
1979年 | 20845篇 |
1978年 | 14847篇 |
1977年 | 12096篇 |
1976年 | 11906篇 |
1975年 | 12132篇 |
1974年 | 14832篇 |
1973年 | 14498篇 |
1972年 | 13360篇 |
1971年 | 12428篇 |
1970年 | 11497篇 |
1969年 | 10419篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
6.
Krishna Pillai Javid Akhter Terence C. Chua Mena Shehata Nayef Alzahrani Issan Al-Alem David L. Morris 《Medicine》2015,94(9)
Thermal ablation of liver tumors near large blood vessels is affected by the cooling effect of blood flow, leading to incomplete ablation. Hence, we conducted a comparative investigation of heat sink effect in monopolar (MP) and bipolar (BP) radiofrequency ablation (RFA), and microwave (MW) ablation devices.With a perfused calf liver, the ablative performances (volume, mass, density, dimensions), with and without heat sink, were measured. Heat sink was present when the ablative tip of the probes were 8.0 mm close to a major hepatic vein and absent when >30 mm away. Temperatures (T1 and T2) on either side of the hepatic vein near the tip of the probes, heating probe temperature (T3), outlet perfusate temperature (T4), and ablation time were monitored.With or without heat sink, BP radiofrequency ablated a larger volume and mass, compared with MP RFA or MW ablation, with latter device producing the highest density of tissue ablated. MW ablation produced an ellipsoidal shape while radiofrequency devices produced spheres.Percentage heat sink effect in Bipolar radiofrequency : Mono-polar radiofrequency : Microwave was (Volume) 33:41:22; (mass) 23:56:34; (density) 9.0:26:18; and (relative elipscity) 5.8:12.9:1.3, indicating that BP and MW devices were less affected.Percentage heat sink effect on time (minutes) to reach maximum temperature (W) = 13.28:9.2:29.8; time at maximum temperature (X) is 87:66:16.66; temperature difference (Y) between the thermal probes (T3) and the temperature (T1 + T2)/2 on either side of the hepatic vessel was 100:87:20; and temperature difference between the (T1 + T2)/2 and temperature of outlet circulating solution (T4), Z was 20.33:30.23:37.5.MW and BP radiofrequencies were less affected by heat sink while MP RFA was the most affected. With a single ablation, BP radiofrequency ablated a larger volume and mass regardless of heat sink. 相似文献
7.
8.
9.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献